The US Food and Drug Administration has authorised the first drug to treat multi-drug resistant tuberculosis involving the lungs in an accelerated approval based on a surrogate endpoint. The drug, Sirturo (bedaquiline), was discovered and developed by Johnson & Johnson Inc.
